Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators ; volume:11 ; number:1 ; day:10 ; month:5 ; year:2023 ; pages:1-22 ; date:12.2023
Acta Neuropathologica Communications ; 11, Heft 1 (10.5.2023), 1-22, 12.2023
- Creator
-
Segura-Collar, Berta
Hiller-Vallina, Sara
Dios, Olaya de
Caamaño-Moreno, Marta
Mondejar-Ruescas, Lucia
Sepulveda-Sanchez, Juan M.
Gargini, Ricardo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40478-023-01569-y
- URN
-
urn:nbn:de:101:1-2023101808270299080523
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Segura-Collar, Berta
- Hiller-Vallina, Sara
- Dios, Olaya de
- Caamaño-Moreno, Marta
- Mondejar-Ruescas, Lucia
- Sepulveda-Sanchez, Juan M.
- Gargini, Ricardo
- SpringerLink (Online service)
Other Objects (12)
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy
Neoantigen‐based vaccines as a promising strategy in cancer immunotherapeutics
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients
Next generation self-replicating RNA vectors for vaccines and immunotherapies
Personalized neoantigen cancer vaccines: current progression, challenges and a bright future
Nanotechnology‐Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives
Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy
Neoantigen‐based vaccines as a promising strategy in cancer immunotherapeutics
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients
Next generation self-replicating RNA vectors for vaccines and immunotherapies
Personalized neoantigen cancer vaccines: current progression, challenges and a bright future
Nanotechnology‐Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives
Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines
Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy
Neoantigen‐based vaccines as a promising strategy in cancer immunotherapeutics
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients
Next generation self-replicating RNA vectors for vaccines and immunotherapies
Personalized neoantigen cancer vaccines: current progression, challenges and a bright future
Nanotechnology‐Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives
Correction: CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies